Thyroid hormone receptor binding to DNA and T3-dependent transcriptional activation are inhibited by uremic toxins

Nuclear Receptor

Volumn 3, Issue , 2005, Pages

  Santos, Guilherme Martins ^a,c   Brasiliense Pantoja, Carlos José Albuquerque ^a   da Costa e Silva, Aluízio ^b   Soares Rodrigues, Maria Cristina ^a   Justiniano Ribeiro, Ralff Carvalho ^d   Simeoni, Luiz Alberto ^a   Lomri, Noureddine ^c   Neves, Francisco A R ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b SOCLIMED Dialysis Unit   (Brazil)

^c UNIVERSITÉ DE CERGY PONTOISE   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; LIOTHYRONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; THYROXINE; UREMIC TOXIN; VITAMIN D RECEPTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; CELL ASSAY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DNA BINDING; ENDOCRINE DISEASE; GENE ACTIVATION; GENETIC TRANSCRIPTION; GOITER; HEMODIALYSIS; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HYPOTHYROIDISM; MALE; PREVALENCE; PROTEIN FUNCTION; RECEPTOR BINDING; THYROID HORMONE RESISTANCE; TISSUE REACTION; UREA BLOOD LEVEL; UREMIA;

EID: 18144372047     PISSN: 14781336     EISSN: None     Source Type: Journal    
DOI: 10.1186/1478-1336-3-1     Document Type: Article

References (39)

1. Casserly LF, Dember LM: Thrombosis in end-stage renal disease. Semin Dial 2003, 16:245-256.
2. Pesanti EL: Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 2001, 15:813-832.
3. Smogorzewski MJ, Massry SG: Liver metabolism in CRF. Am J Kidney Dis 2003, 41:S127-132.
4. Strid H, Simren M, Stotzer PO, Ringstrom G, Abrahamsson H, Bjornsson ES: Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion 2003, 67:129-137.
5. Bommer C, Werle E, Walter-Sack I, Keller C, Gehlen F, Wanner C, Nauck M, Marz W, Wieland H, Bommer J: D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. J Am Soc Nephrol 1998, 9:90-96.
6. Diez JJ, Iglesias P, Selgas R: Pituitary dysfunctions in uremic patients undergoing peritoneal dialysis: a cross sectional descriptive study. Adv Perit Dial 1995, 11:218-224.
7. Lin CC, Chen TW, Ng YY, Chou YH, Yang WC: Thyroid dysfunction and nodular goiter in hemodialysis and peritoneal dialysis patients. Perit Dial Int 1998, 18:516-521.
8. Lukinac L, Kusic Z, Kes P, Nothig-Hus D: Effect of chronic hemodialysis on thyroid function tests in patients with end-stage renal disease. Acta Med Croatica 1996, 50:65-68.
9. Lim VS: Thyroid function in patients with chronic renal failure. Am J Kidney Dis 2001, 38:S80-84.
10. Kaptein EM, Quion-Verde H, Chooljian CJ, Tang WW, Friedman PE, Rodriquez HJ, Massry SG: The thyroid in end-stage renal disease. Medicine (Baltimore) 1988, 67:187-197.
11. Medri G, Carella C, Padmanabhan V, Rossi CM, Amato G, De Santo NG, Beitins IZ, Beck-Peccoz P: Pituitary glycoprotein hormones in chronic renal failure: evidence for an uncontrolled alpha-subunit release. J Endocrinol Invest 1993, 16:169-174.
12. Lim VS, Fang VS, Katz AI, Refetoff S: Thyroid dysfunction in chronic renal failure. A study of the pituitary-thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine. J Clin Invest 1977, 60:522-534.
13. Lim VS, Flanigan MJ, Zavala DC, Freeman RM: Protective adaptation of low serum triiodothyronine in patients with chronic renal failure. Kidney Int 1985, 28:541-549.
14. Ribeiro RCJ, Apriletti JW, West BL, Wagner RL, Fletterick RJ, Schaufele F, Baxter JD: The molecular biology of thyroid hormone action. Ann N Y Acad Sci 1995, 758:366-389.
15. Yen PM: Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001, 81:1097-1142.
16. Hohenegger M, Vermes M, Esposito R, Giordano C: Effect of some uremic toxins on oxygen consumption of rats in vivo and in vitro. Nephron 1988, 48:154-158.
17. Lim VS, Zavala DC, Flanigan MJ, Freeman RM: Blunted peripheral tissue responsiveness to thyroid hormone in uremic patients. Kidney Int 1987, 31:808-814.
18. Spector DA, Davis PJ, Helderman JH, Bell B, Utiger RD: Thyroid function and metabolic state in chronic renal failure. Ann Intern Med 1976, 85:724-730.
19. Aranda A, Pascual A: Nuclear hormone receptors and gene expression. Physiol Rev 2001, 81:1269-1304.
20. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
21. Umesono K, Evans RM: Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 1989, 57:1139-1146.
22. Umesono K, Murakami KK, Thompson CC, Evans RM: Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 1991, 65:1255-1266.
23. Ribeiro RC, Apriletti JW, Yen PM, Chin WW, Baxter JD: Heterodimerization and deoxyribonucleic acid-binding properties of a retinoid X receptor-related factor. Endocrinology 1994, 135:2076-2085.
24. Hsu CH, Patel SR: Altered vitamin D metabolism and receptor interaction with the target genes in renal failure: calcitriol receptor interaction with its target gene in renal failure. Curr Opin Nephrol Hypertens 1995, 4:302-306.
25. Hsu CH, Patel SR, Young EW, Vanholder R: The biological action of calcitriol in renal failure. Kidney Int 1994, 46:605-612.
26. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH: Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 1995, 96:50-59.
27. Sawaya BP, Koszewski NJ, Qi Q, Langub MC, Monier-Faugere MC, Malluche HH: Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. J Am Soc Nephrol 1997, 8:271-278.
28. Toell A, Degenhardt S, Grabensee B, Carlberg C: Inhibitory effect of uremic solutions on protein-DNA-complex formation of the vitamin D receptor and other members of the nuclear receptor superfamily. J Cell Biochem 1999, 74:386-394.
29. Hsu CH, Patel SR: Uremic toxins and vitamin D metabolism. Kidney Int Suppl 1997, 62:S65-68.
30. Lee CH, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
31. Stefanovic V, Nesic V, Stojimirovic B: Treatment of insulin resistance in uremia. Int J Artif Organs 2003, 26:100-104.
32. De Groot LJ: Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 1999, 84:151-164.
33. McIver B, Gorman CA: Euthyroid sick syndrome: an overview. Thyroid 1997, 7:125-132.
34. Wartofsky L, Burman KD: Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". Endocr Rev 1982, 3:164-217.
35. Rodrigues MC, Santos GM, da Silva CA, Baxter JD, Webb P, Lomri N, Neves FA, Ribeiro RC, Simeoni LA: Thyroid hormone transport is disturbed in erythrocytes from patients with chronic renal failure on hemodialysis. Ren Fail 2004, 26:461-466.
36. Patel SR, Ke HQ, Vanholder R, Hsu CH: Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate. Kidney Int 1994, 46:129-133.
37. Dusso AS: Vitamin D receptor: Mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl 2003:6-9.
38. Ribeiro RC, Feng W, Wagner RL, Costa CH, Pereira AC, Apriletti JW, Fletterick RJ, Baxter JD: Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. J Biol Chem 2001, 276:14987-14995.
39. Chen S, Cui J, Nakamura K, Ribeiro RC, West BL, Gardner DG: Coactivator-vitamin D receptor interactions mediate inhibition of the atrial natriuretic peptide promoter. J Biol Chem 2000, 275:15039-15048.